Paper Details
- Home
- Paper Details
The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
Author: HagiharaMasao, HuaJian, InoueMorihiro, UchidaTomoyuki
Original Abstract of the Article :
We reviewed the cases of 68 consecutive patients who were diagnosed with myelodysplastic syndrome (MDS, n=61) or acute erythroleukemia (AEL, n=7) according to the World Health Organization (WHO) 2008 criteria and had previously been treated with azacitidine, a hypomethylating agent. Fifteen MDS pati...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1016/j.leukres.2016.11.012
データ提供:米国国立医学図書館(NLM)
Azacitidine: A Promising Treatment for Myelodysplastic Syndrome and Acute Myeloid Leukemia
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) can be daunting challenges, like navigating a scorching desert with limited resources. This study investigates the effectiveness of azacitidine, a hypomethylating agent, in treating these blood cancers, particularly in patients with high erythroblast frequencies, which are immature red blood cells.
The researchers reviewed data from 68 patients with MDS and AML, comparing the outcomes of those with high erythroblast frequencies to those with lower counts. They found that azacitidine was effective in both groups, leading to hematological improvement in a significant proportion of patients. The study also found that the survival outcomes were comparable between the two groups, suggesting that azacitidine can be a valuable treatment option regardless of erythroblast frequency.
Navigating the Complexities of Blood Cancers
This study highlights the importance of individualized treatment approaches for blood cancers. It emphasizes the need to consider all relevant factors, such as erythroblast frequency, when selecting the most effective therapy.
Hope in the Desert of Blood Cancer Treatment
This study provides a beacon of hope for patients with MDS and AML. It demonstrates that azacitidine can be a valuable tool in combating these challenging diseases, offering the potential for hematological improvement and prolonged survival.
Dr. Camel's Conclusion
In the desert of blood cancer treatment, researchers are continuously searching for new oases of hope. This study underscores the potential of azacitidine as a therapeutic tool for MDS and AML, offering a beacon of light for those navigating this challenging journey. Remember to consult with a qualified healthcare professional to discuss the best treatment approach for your individual needs.
Date :
- Date Completed 2017-07-28
- Date Revised 2018-04-30
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.